Endocrine Abstracts

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that promotes degradation of the low density lipoprotein (LDL) receptor, has been emerged as a novel therapeutic target for the dyslipidemia. It is well known that the pathogenesis of cardiovascular disease (CVD) involves lipid metabolism alteration, but the predictive value of circulating PCSK9 level concerning coronary disease severity is largely unknown. The main objective of this study is to deter...